Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection and Hemophilia
jRCT2031260207Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of foscenvivint in Cirrhosis, human immunodeficiency virus infection (HIV), hepatitis C virus infection and 1 more, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change in ALBI score at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
foscenvivint
03
Conditions
Cirrhosishuman immunodeficiency virus infection (HIV)hepatitis C virus infectionhemophilia
Beyond the preview
Go deeper on jRCT2031260207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260207.